2005
DOI: 10.1542/peds.2004-1014
|View full text |Cite
|
Sign up to set email alerts
|

Use of Cholecystokinin-Octapeptide for the Prevention of Parenteral Nutrition-Associated Cholestasis

Abstract: Use of CCK-OP failed to reduce significantly the incidence of PNAC or levels of CB. CCK-OP had no effect on other secondary measures and should not be recommended for the prevention of PNAC.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
31
0

Year Published

2006
2006
2019
2019

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 68 publications
(31 citation statements)
references
References 40 publications
0
31
0
Order By: Relevance
“…However, to date, studies testing prophylactic strategies have not identified a consistently successful method, other than discontinuing the PN, which frequently is not a feasible option. Those studies included prophylactic administration of taurosusodeoxycholic acid, 5 cholecystokinin-octapeptide, 6,7 taurine, 8 phenobarbitol 9 and removing copper and manganese from the PN. 10,11 One problem inherent in any prophylactic strategy in the NICU is accurately predicting which neonates are at highest risk for developing the adverse outcome, so that high-risk patients can be eligible for study while low-risk patients can be excluded.…”
Section: Introductionmentioning
confidence: 99%
“…However, to date, studies testing prophylactic strategies have not identified a consistently successful method, other than discontinuing the PN, which frequently is not a feasible option. Those studies included prophylactic administration of taurosusodeoxycholic acid, 5 cholecystokinin-octapeptide, 6,7 taurine, 8 phenobarbitol 9 and removing copper and manganese from the PN. 10,11 One problem inherent in any prophylactic strategy in the NICU is accurately predicting which neonates are at highest risk for developing the adverse outcome, so that high-risk patients can be eligible for study while low-risk patients can be excluded.…”
Section: Introductionmentioning
confidence: 99%
“…Cholecystokinin is a gastrointestinal hormone that has been shown to promote choleresis [17,18] , and was suggested in a retrospective cohort study to prevent severe conjugated hyperbilirubinemia (defined as direct bilirubin 6 5.0 mg/dl) [19] . However, a recent large multicenter double-blind, randomized, controlled trial of cholecystokinin-octapeptide in neonates did not show any effect on conjugated bilirubin levels, incidence of biliary sludge or cholelithiasis formation [15] . Cholecystectomy is used commonly in adults but not in neonates.…”
Section: Discussionmentioning
confidence: 88%
“…In addition to saline, lavage with the mucolytic agent N-acetylcysteine [13] has been described. Other modalities have been described, including enterallyadministered ursodeoxycholic acid [14] , parenterally-administered cholecystokinin [15] , and cholecystectomy [5] .…”
Section: Discussionmentioning
confidence: 99%
“…As early as 3-4 days after the start of TPN, gallbladder distension and formation of sludge have been diagnosed in term and preterm neonates [1,2,9] . Concerns regarding parenteral nutrition-associated cholestasis resulted in considerable efforts for their prevention [10] . These failed to prove efficacious.…”
Section: Discussionmentioning
confidence: 99%